AR061598A1 - Nitroderivados heterociclicos como antagonistas de receptor de endotelina - Google Patents
Nitroderivados heterociclicos como antagonistas de receptor de endotelinaInfo
- Publication number
- AR061598A1 AR061598A1 ARP070102313A ARP070102313A AR061598A1 AR 061598 A1 AR061598 A1 AR 061598A1 AR P070102313 A ARP070102313 A AR P070102313A AR P070102313 A ARP070102313 A AR P070102313A AR 061598 A1 AR061598 A1 AR 061598A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- ono2
- integer
- defined above
- equal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Se pueden emplear para tratar o prevenir trastornos relacionados con el endotelio, enfermedades renales, pulmonares, cardíacos y enfermedades vasculares, y procesos inflamatorios. Usos y composicion farmacéutica. Reivindicacion 1: Un compuesto de la formula general o una de sus sales o estereoisomeros farmacéuticamente aceptables: (1) caracterizado porque: m, m' y m'' son iguales a 0 o 1; n, n' y n'' son iguales a 0 o 1; s, s' y s'' son iguales a 0 o 1; A se selecciona del grupo que consiste en: (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13), (14), (15), (16), (17), (18), (19), (20), (21), (22), en donde: N1 es -O-, -OH; N2 es -N-, -NH-; N3 es -C(O)O-, -C(O)NH-; B, B' y B'' son -CO-, -C(O)O-, -C(O)NH; C, C' y C'' son: - C(CH3)H-O-C(=O)-O-, -CH2-O-C(=O)-O-, -(CH3)2 HC-O-C=O)-O-; con la condicion de que: 1) cuando a se selecciona del grupo que consiste en: (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13) y (14), al menos uno de m, m', m'', n, n' o n'' sea 1; 2) cuando A se selecciona del grupo que consiste en: (15), (16), (17), (18), (19), (20) y (22), entonces s', s'' y m sean 0; mientras que n es 0 o 1; 3) cuando A es (21), entonces m, m' y s'' sean 0; mientras que n y n' son 0 o 1, 4) al menos uno de N1 o N2 sea un grupo -O- o -N- capaz de ligar al menos uno de los grupos -[(B)m-(C)n-(Y-ONO2)], -[(B')m'-(C')n'-(Y'-ONO2)] o -[(B'')m''-(C'')n''-(Y''-ONO2)]; Y, Y' e Y'' son un radical bivalente con el siguiente significado: a) -alquileno C1- 20 lineal o ramificado, opcionalmente sustituido con uno o más de los sustituyentes seleccionados del grupo que consiste en: átomos de halogeno, hidroxi, -ONO2 o Ta, en donde Ta es -OC(O)(alquilo C1-10)-ONO2 o -O(alquilo C1-10)-ONO2; -cicloalquileno con 5 a 7 átomos de carbono en un anillo cicloalquileno, en donde el anillo está opcionalmente sustituido con cadenas laterales T, en donde T es alquilo lineal o ramificado con 1 a 10 átomos de carbono; b) (23), c) (24) en donde n0 es un entero de 0 a 20, y n1 es un entero de 1 a 20; d) (25) en donde: n1 es tal como se definio con anterioridad y n2 es un entero de 0 a 2; X1 = -OCO- o -COO- y R2 es H o CH3; e) (26) en donde: n1, n2, R2 y X1 son tal como se definio con anterioridad; Y1 es -CH2- CH2- o -CH=CH-(CH2)n2-; f) (27) en donde: n1 y R2 son tal como se definio con anterioridad, R3 es H o -COCH3; con la condicion de que cuando Y se selecciona de los radicales bivalentes mencionados en b)-f), el grupo -ONO2 esté ligado a un grupo - CH2; -(CH(R2)-CH2-X2)n3-CH(R2)- CH2-, -(CH2-CH(R2)-X2)n3-CH2-CH(R2)- en donde X2 es -O- o -S-, n3 es un entero de 1 a 6, R2 es tal como se definio con anterioridad; h) -[C(R4R6)]n4-Y2-[C(R5R7)]n5 en donde: n4 es un entero de 0 a 10; n5 es un entero de 1 a 10; R4, R5, R6, R7 son iguales o diferentes, y son H o alquilo C1-4 lineal o ramificado; en donde el grupo -ONO2 está ligado a >=[C]n5 en donde n5 es tal como se definio con anterioridad; Y2 es un anillo heterocíclico saturado, insaturado o aromático de 5 o 6 miembros, que contiene uno o más heteroátomos seleccionados de nitrogeno, oxígeno o azufre, y se selecciona del grupo que consiste en (28).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06114617 | 2006-05-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR061598A1 true AR061598A1 (es) | 2008-09-10 |
Family
ID=38255421
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070102313A AR061598A1 (es) | 2006-05-29 | 2007-05-29 | Nitroderivados heterociclicos como antagonistas de receptor de endotelina |
Country Status (16)
Country | Link |
---|---|
US (1) | US20090263472A1 (es) |
EP (1) | EP2021324B1 (es) |
JP (1) | JP2009538862A (es) |
KR (1) | KR20090020559A (es) |
CN (1) | CN101454283A (es) |
AR (1) | AR061598A1 (es) |
AT (1) | ATE537144T1 (es) |
AU (1) | AU2007267209A1 (es) |
BR (1) | BRPI0711315A2 (es) |
CA (1) | CA2652636A1 (es) |
MX (1) | MX2008015289A (es) |
NO (1) | NO20085375L (es) |
NZ (1) | NZ571820A (es) |
RU (1) | RU2008150440A (es) |
WO (1) | WO2007137980A1 (es) |
ZA (1) | ZA200808766B (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR073259A1 (es) * | 2008-07-29 | 2010-10-28 | Merck & Co Inc | Derivados de furosemida utiles como diureticos |
WO2010096320A2 (en) * | 2009-02-18 | 2010-08-26 | Bezwada Biomedical, Llc | Controlled release of nitric oxide and drugs from functionalized macromers and oligomers |
WO2011070049A1 (en) * | 2009-12-09 | 2011-06-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Endothelin inhibitors for the treatment of rapidly progressive glomerulonephritis |
WO2012152438A1 (en) * | 2011-05-11 | 2012-11-15 | Nicox S.A. | Process for the preparation of nitrate acid ester of organic compounds |
WO2015055825A1 (en) | 2013-10-18 | 2015-04-23 | Attoquant Diagnostics Gmbh | Method for diagnosis of primary hyperaldosteronism |
CN116194449B (zh) * | 2021-09-03 | 2024-07-26 | 深圳信立泰药业股份有限公司 | 一种内皮素a(eta)受体拮抗剂化合物及其制备方法和医药用途 |
CN113943266A (zh) * | 2021-11-18 | 2022-01-18 | 广州楷石医药有限公司 | 一种氧化氮供体型贝前列素类衍生物及其药物组合物和用途 |
CN115959996A (zh) * | 2022-01-28 | 2023-04-14 | 上海众强药业有限公司 | No供体化合物及其药物组合物和应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2195002T3 (es) * | 1995-08-02 | 2003-12-01 | Smithkline Beecham Corp | Antagonistas de los receptores de la endotelina. |
CA2391818A1 (en) | 1996-03-13 | 1997-09-18 | Queen's University At Kingston | Antagonism of endothelin actions |
ID25620A (id) * | 1997-09-04 | 2000-10-19 | Basf Ag | Turunan-turunan asam karboksilat baru, pembuatannya dan penggunaannya sebagai campuran reseptor antagonis et a/et b |
TWI284642B (en) | 1999-01-18 | 2007-08-01 | Hoffmann La Roche | Novel heterocyclic sulfonamides |
EP1244455B1 (en) | 1999-10-29 | 2009-07-22 | Nitromed, Inc. | Methods of treating vascular diseases characterized by nitric oxide insufficiency |
CA2536975A1 (en) | 2003-08-28 | 2005-03-17 | Nitromed, Inc. | Nitrosated and nitrosylated diuretic compounds, compositions and methods of use |
-
2007
- 2007-05-23 AU AU2007267209A patent/AU2007267209A1/en not_active Abandoned
- 2007-05-23 BR BRPI0711315-3A patent/BRPI0711315A2/pt not_active IP Right Cessation
- 2007-05-23 MX MX2008015289A patent/MX2008015289A/es active IP Right Grant
- 2007-05-23 WO PCT/EP2007/055012 patent/WO2007137980A1/en active Application Filing
- 2007-05-23 JP JP2009512550A patent/JP2009538862A/ja not_active Withdrawn
- 2007-05-23 NZ NZ571820A patent/NZ571820A/en not_active IP Right Cessation
- 2007-05-23 US US12/300,026 patent/US20090263472A1/en not_active Abandoned
- 2007-05-23 EP EP07729447A patent/EP2021324B1/en active Active
- 2007-05-23 CA CA002652636A patent/CA2652636A1/en not_active Abandoned
- 2007-05-23 AT AT07729447T patent/ATE537144T1/de active
- 2007-05-23 KR KR1020087026471A patent/KR20090020559A/ko not_active Application Discontinuation
- 2007-05-23 CN CNA2007800199691A patent/CN101454283A/zh active Pending
- 2007-05-23 RU RU2008150440/04A patent/RU2008150440A/ru not_active Application Discontinuation
- 2007-05-29 AR ARP070102313A patent/AR061598A1/es unknown
-
2008
- 2008-10-14 ZA ZA200808766A patent/ZA200808766B/xx unknown
- 2008-12-23 NO NO20085375A patent/NO20085375L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
ZA200808766B (en) | 2010-01-27 |
NZ571820A (en) | 2010-09-30 |
AU2007267209A1 (en) | 2007-12-06 |
JP2009538862A (ja) | 2009-11-12 |
WO2007137980A1 (en) | 2007-12-06 |
EP2021324B1 (en) | 2011-12-14 |
MX2008015289A (es) | 2008-12-12 |
CN101454283A (zh) | 2009-06-10 |
BRPI0711315A2 (pt) | 2011-11-29 |
CA2652636A1 (en) | 2007-12-06 |
KR20090020559A (ko) | 2009-02-26 |
NO20085375L (no) | 2009-02-25 |
RU2008150440A (ru) | 2010-07-20 |
EP2021324A1 (en) | 2009-02-11 |
US20090263472A1 (en) | 2009-10-22 |
ATE537144T1 (de) | 2011-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR061598A1 (es) | Nitroderivados heterociclicos como antagonistas de receptor de endotelina | |
AR061858A1 (es) | Compuestos heterociclicos de fosfonatos y fosfinatos, composiciones farmaceuticas que los contienen y usos como agentes antidiabeticos. | |
EA201200669A1 (ru) | ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα | |
EA200800760A1 (ru) | ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα | |
AR033678A1 (es) | Derivados de quinolina, procedimiento para prepararlos, uso de los mismos para la preparacion de medicamentos y los medicamentos que contienen dichos derivados | |
AR047081A1 (es) | Derivados de prostaglandinas, metodos para su preparacion, composiciones farmaceuticas que las contienen y su uso en el tratamiento del glaucoma y de la hipertension ocular. | |
EA201071329A1 (ru) | Диамидные производные адамантана и их применение | |
AR060768A1 (es) | Compuestos de imidazol sustituidos inhibidores del factor x, composiciones farmaceuticas que los contienen y usos como agentes antitromboticos. | |
AR064370A1 (es) | Nitroderivados de bencenosulfonamidas sustituidas como inhibidores de anhidrasa carbonica composiciones farmaceuticas que los comprenden kits farmaceuticos para su administracion y su uso en la preparacion de un medicamento para el tratamiento del cancer y de trastornos oculares | |
EA200602060A1 (ru) | Производные пирролидин-2-она и пиперидин-2-она, используемые в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы | |
AR045145A1 (es) | Nitro-oxi derivados bloqueadores del receptor de angiotensina ii | |
ATE440833T1 (de) | Antithrombotische diamide | |
EA202092975A1 (ru) | Селективные супрессоры рецептора эстрогена | |
EA200501327A1 (ru) | Пиримидины и триазины, ингибирующие вич репликацию | |
EA200870358A1 (ru) | 2-(циклический амино) пиримидоновые производные в качестве ингибиторов tpk1 | |
UY30141A1 (es) | Nuevas isoindolonas potenciadoras de receptores metabotropicos de glutamato | |
EA201390908A1 (ru) | Производные бицикло[3.2.1]октиламида и их применение | |
EA200971115A1 (ru) | Новые ингибиторы обратной транскриптазы вич | |
EA201171328A1 (ru) | Производное замещенного изохинолина | |
PE20070171A1 (es) | GLICINAMIDAS SUSTITUIDAS CON EFECTO ANTITROMBOTICO E INHIBIDOR DEL FACTOR Xa | |
AR056868A1 (es) | Nitrooxi derivados de esteroides, composiciones farmaceuticas y su uso para tratar trastornos de la piel o de la membrana mucosa | |
AR044561A1 (es) | Derivados de estatina | |
UY29690A1 (es) | Derivados de n-(heteroaril)-1-heteroarilalquil-1h-indol-2-carboxamidas, su preparación y su aplicación en terapéutica. | |
AR054790A1 (es) | Metodos para el tratamiento de disfuncion sexual | |
AR053340A1 (es) | Derivados de trifluormetilbenzamida y sus usos terapeuticos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |